Further, in a study published by Tury and colleagues, the COX-2-selective inhibitor celecoxib was effective against PIK3CA-mutated patient-derived breast cancer xenografts, but not against PIK3CA-wildtype xenografts [197]. Here, PIK3CA is linked to breast cancer.